Key result
Low-dose digoxin fails to reduce worsening heart failure events or CV mortality vs placebo.
Why the study?
The value of low-dose digoxin in the current management of heart failure with reduced or mildly reduced ejection fraction was unclear and lacked evidence from rigorous randomized clinical trials.
Does low-dose digoxin reduce the composite of total worsening heart failure events and cardiovascular mortality in patients with heart failure with reduced or mildly reduced ejection fraction?
RCT (n=1,001)
Double-blind
randomly assigned
Yes
Does low-dose digoxin reduce the composite of total worsening heart failure events and cardiovascular mortality in patients with heart failure with reduced or mildly reduced ejection fraction?
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The DECISION trial is the first randomized controlled trial in the current era of treatment with the four pillars of HF therapy. While digoxin did not significantly reduce the composite endpoint in this trial, it substantially reduced the combination of cardiovascular death and worsening heart failure events by 19%. That's a large effect.”
“In patients with HFmrEF, low-dose digitalis glycosides seem to be an effective additional medical treatment option, which are cheap, safe and easy to use. The totality of the evidence supports the role of low-dose digoxin in the contemporary management of HF, with caution warranted when it is stopped.”
In patients with heart failure and reduced or mildly reduced ejection fraction, adding low-dose digoxin to contemporary guideline-directed medical therapy did not significantly reduce total worsening heart failure events or cardiovascular mortality, though it was safe and well tolerated.
Digoxin is the oldest drug in cardiovascular medicine, but its value in the current management of heart failure is unclear. Earlier studies have suggested that low-dose digoxin might be beneficial, but evidence from rigorous randomized clinical trials is lacking. In this double-blind, placebo-controlled trial (the DECISION trial), 1,001 patients with symptomatic chronic heart failure and a left ventricular ejection fraction of 50% or less were randomized to low-dose digoxin or placebo, with a target serum digoxin concentration of 0.5–0.9 ng ml−1. The mean age of the participants was 72 ± 9 years, 28% were women and 29% had atrial fibrillation. The primary outcome was a composite of total worsening heart failure events, defined as total hospitalizations or total urgent hospital visits for worsening heart failure and cardiovascular mortality. Over a median follow-up of 36.5 months, 238 primary-outcome events occurred in 131 of 500 patients in the digoxin group, and 291 primary-outcome events in 152 of 501 patients occurred in the placebo group (rate ratio 0.81; 95% confidence interval (CI) 0.61–1.07, P = 0.133). The total number of worsening heart failure events was 155 and 203 in the digoxin and placebo groups, respectively (rate ratio 0.76, 95% CI 0.54–1.05) and cardiovascular mortality occurred in 83 patients (17%) and 88 (18%) in the digoxin and placebo groups, respectively (hazard ratio 0.93, 95% CI 0.69–1.26). Low-dose digoxin was generally well tolerated and safe, and results were similar between men and women. The results of this trial indicate that in patients with heart failure and reduced or mildly reduced ejection fraction, low-dose digoxin did not significantly reduce the composite endpoint of total worsening heart failure events or cardiovascular mortality. ClinicalTrials.gov registration: NCT03783429 . As presented at the 2026 ESC Heart Failure Congress, in a large randomized controlled trial in patients with heart failure with reduced or mildly reduced ejection fraction, treatment with low-dose digoxin was generally safe and well tolerated, but did not significantly reduce the composite endpoint of total worsening heart failure events or cardiovascular mortality.
Veldhuisen et al. (2026) conducted an RCT in Heart failure with reduced or mildly reduced ejection fraction (n=1,001). Low-dose digoxin vs. Placebo was evaluated on Composite of total worsening heart failure events (hospitalizations or urgent visits) and cardiovascular mortality (rate ratio 0.81, 95% CI 0.61-1.07, p=0.133). Low-dose digoxin did not reduce the composite endpoint of total worsening heart failure events or cardiovascular mortality compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: